Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Genitourinary Cancer Specialty Channel

Genitourinary Cancer
Specialty Channel
Martijn Meijerink, MD, PhD, Amsterdam UMC
Videos
Thermal Ablation Non-Inferior to Surgery for Patients With Smaller Colorectal Liver Metastases
06/19/2024
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD,...
06/19/2024
Oncology
Quiz
Quiz: Which Immunotherapy First Demonstrated Statistically Significant Survival Benefit in R/M Cervical Carcinoma?
03/29/2022
In the largest randomized study conducted to date in this population, ________ is the first immunotherapy to demonstrate a statistically significant and clinically meaningful survival benefit in R/M cervical carcinoma following progression...
In the largest randomized study conducted to date in this population, ________ is the first immunotherapy to demonstrate a statistically significant and clinically meaningful survival benefit in R/M cervical carcinoma following progression...
In the largest randomized study...
03/29/2022
Oncology
News
Sacituzumab Govitecan Advised as Potential Combination Therapy With Pembrolizumab in mUC
02/23/2022
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be...
02/23/2022
Oncology
Test Your Knowledge
Quiz: What is the Clinical Benefit Rate of Niraparib Plus Dostarlimab in Recurrent Endometrial Carcinoma?
11/29/2021
According to data presented at the ASCO Annual Meeting, the combination of niraparib and dostarlimab displays a clinical benefit rate of _______ at 16w in patients with recurrent endometrial carcinoma.
According to data presented at the ASCO Annual Meeting, the combination of niraparib and dostarlimab displays a clinical benefit rate of _______ at 16w in patients with recurrent endometrial carcinoma.
According to data presented at...
11/29/2021
Oncology
Test Your Knowledge
Quiz: Which Trial Evaluated Niraparib With or Without Dostarlimab in Recurrent Endometrial Carcinoma?
11/24/2021
The _____ multicentric trial evaluated dostarlimab in combination with niraparib versus niraparib alone, compared to chemotherapy, in the treatment of endometrial/ovarian carcinosarcoma following at least one line of platinum based...
The _____ multicentric trial evaluated dostarlimab in combination with niraparib versus niraparib alone, compared to chemotherapy, in the treatment of endometrial/ovarian carcinosarcoma following at least one line of platinum based...
The _____ multicentric trial...
11/24/2021
Oncology
Test Your Knowledge
Quiz: How Are Germline Varients Prevelant in Unselected EC?
11/23/2021
True or False: The enrichment of germline BRCA1/2 PVs in type II cancers is consistent with prior reports that non-endometrioid tumors are frequently deficient in homologous recombination.
True or False: The enrichment of germline BRCA1/2 PVs in type II cancers is consistent with prior reports that non-endometrioid tumors are frequently deficient in homologous recombination.
True or False: The enrichment of...
11/23/2021
Oncology
News
FDA Approves Sacituzumab Govitecan for Advanced Urothelial Cancer
04/13/2021
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated...
04/13/2021
Oncology
Test Your Knowledge
Quiz: Risk of Recurrence and Progression for Patients with NMIBC
02/19/2021
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does...
02/19/2021
Oncology
News
Study Predicts Risk of Recurrence, Progression for Patients With NMIBC
02/19/2021
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based...
02/19/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment Received FDA Approval for Metastatic Urothelial Carcinoma?
11/03/2020
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by...
11/03/2020
Oncology
Test Your Knowledge
Quiz: Is Ipilimumab Plus Nivolumab Active in Patients with Metastatic RCC?
07/31/2020
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
True or false: Ipilimumab plus...
07/31/2020
Oncology

Advertisement

News

Martijn Meijerink, MD, PhD, Amsterdam UMC
Videos
Thermal Ablation Non-Inferior to Surgery for Patients With Smaller Colorectal Liver Metastases
06/19/2024
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD,...
06/19/2024
Oncology
News
Sacituzumab Govitecan Advised as Potential Combination Therapy With Pembrolizumab in mUC
02/23/2022
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be...
02/23/2022
Oncology
News
FDA Approves Sacituzumab Govitecan for Advanced Urothelial Cancer
04/13/2021
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated...
04/13/2021
Oncology
News
Study Predicts Risk of Recurrence, Progression for Patients With NMIBC
02/19/2021
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based...
02/19/2021
Oncology
News
Salvage Ipilimumab Plus Nivolumab Active in Metastatic RCC
07/29/2020
Ipilimumab plus nivolumab yielded anti-tumor activity with acceptable toxicity in patients with metastatic RCC previously given immune checkpoint inhibitors.
Ipilimumab plus nivolumab yielded anti-tumor activity with acceptable toxicity in patients with metastatic RCC previously given immune checkpoint inhibitors.
Ipilimumab plus nivolumab...
07/29/2020
Oncology
News
Pembrolizumab Yields Meaningful Benefit in Advanced Urothelial Cancer
07/27/2020
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
Pembrolizumab was active in...
07/27/2020
Oncology
News
FDA Approves Avelumab for Advanced or Metastatic Urothelial Carcinoma
07/01/2020
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing chemotherapy.
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing chemotherapy.
The FDA approved avelumab for...
07/01/2020
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
News
Switch Maintenance Pembrolizumab Improves Response, PFS in Metastatic Urothelial Cancer
05/01/2020
Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.
Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.
Switch maintenance pembrolizumab...
05/01/2020
Oncology
News
Teratoma Not A Prognostic Factor in Metastatic Testicular Germ Cell Tumors
05/01/2020
Findings from a large retrospective study suggest that teratoma is not a prognostic factor in patients with metastatic testicular germ cell tumors.
Findings from a large retrospective study suggest that teratoma is not a prognostic factor in patients with metastatic testicular germ cell tumors.
Findings from a large...
05/01/2020
Oncology

Interactive Features

Quiz
Quiz: Which Immunotherapy First Demonstrated Statistically Significant Survival Benefit in R/M Cervical Carcinoma?
03/29/2022
In the largest randomized study conducted to date in this population, ________ is the first immunotherapy to demonstrate a statistically significant and clinically meaningful survival benefit in R/M cervical carcinoma following progression...
In the largest randomized study conducted to date in this population, ________ is the first immunotherapy to demonstrate a statistically significant and clinically meaningful survival benefit in R/M cervical carcinoma following progression...
In the largest randomized study...
03/29/2022
Oncology
Test Your Knowledge
Quiz: What is the Clinical Benefit Rate of Niraparib Plus Dostarlimab in Recurrent Endometrial Carcinoma?
11/29/2021
According to data presented at the ASCO Annual Meeting, the combination of niraparib and dostarlimab displays a clinical benefit rate of _______ at 16w in patients with recurrent endometrial carcinoma.
According to data presented at the ASCO Annual Meeting, the combination of niraparib and dostarlimab displays a clinical benefit rate of _______ at 16w in patients with recurrent endometrial carcinoma.
According to data presented at...
11/29/2021
Oncology
Test Your Knowledge
Quiz: Which Trial Evaluated Niraparib With or Without Dostarlimab in Recurrent Endometrial Carcinoma?
11/24/2021
The _____ multicentric trial evaluated dostarlimab in combination with niraparib versus niraparib alone, compared to chemotherapy, in the treatment of endometrial/ovarian carcinosarcoma following at least one line of platinum based...
The _____ multicentric trial evaluated dostarlimab in combination with niraparib versus niraparib alone, compared to chemotherapy, in the treatment of endometrial/ovarian carcinosarcoma following at least one line of platinum based...
The _____ multicentric trial...
11/24/2021
Oncology
Test Your Knowledge
Quiz: How Are Germline Varients Prevelant in Unselected EC?
11/23/2021
True or False: The enrichment of germline BRCA1/2 PVs in type II cancers is consistent with prior reports that non-endometrioid tumors are frequently deficient in homologous recombination.
True or False: The enrichment of germline BRCA1/2 PVs in type II cancers is consistent with prior reports that non-endometrioid tumors are frequently deficient in homologous recombination.
True or False: The enrichment of...
11/23/2021
Oncology
Test Your Knowledge
Quiz: Risk of Recurrence and Progression for Patients with NMIBC
02/19/2021
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does...
02/19/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment Received FDA Approval for Metastatic Urothelial Carcinoma?
11/03/2020
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by...
11/03/2020
Oncology
Test Your Knowledge
Quiz: Is Ipilimumab Plus Nivolumab Active in Patients with Metastatic RCC?
07/31/2020
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
True or false: Ipilimumab plus...
07/31/2020
Oncology
Test Your Knowledge
Quiz: Is Enfortumab Vedotin an Effective Therapy for Metastatic Urothelial Cancer?
06/22/2020
True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.
True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.
True or False: Enfortumab...
06/22/2020
Oncology
Test Your Knowledge
Quiz: Is Teratoma a Prognostic Factor in Testicular Germ Cell Tumors?
05/05/2020
True or false: Teratoma is a prognostic factor in patients with metastatic testicular germ cell tumors.
True or false: Teratoma is a prognostic factor in patients with metastatic testicular germ cell tumors.
True or false: Teratoma is a...
05/05/2020
Oncology
Test Your Knowledge
Quiz: Does Nivolumab–Ipilimumab Yield Long-Term Benefit in Advanced RCC?
10/01/2019
True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.
True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.
True or False: Combining...
10/01/2019
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Sacituzumab Govitecan Advised as Potential Combination Therapy With Pembrolizumab in mUC
02/23/2022
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be...
02/23/2022
Oncology
News
FDA Approves Sacituzumab Govitecan for Advanced Urothelial Cancer
04/13/2021
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated...
04/13/2021
Oncology
News
Study Predicts Risk of Recurrence, Progression for Patients With NMIBC
02/19/2021
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based...
02/19/2021
Oncology
News
Salvage Ipilimumab Plus Nivolumab Active in Metastatic RCC
07/29/2020
Ipilimumab plus nivolumab yielded anti-tumor activity with acceptable toxicity in patients with metastatic RCC previously given immune checkpoint inhibitors.
Ipilimumab plus nivolumab yielded anti-tumor activity with acceptable toxicity in patients with metastatic RCC previously given immune checkpoint inhibitors.
Ipilimumab plus nivolumab...
07/29/2020
Oncology
News
Pembrolizumab Yields Meaningful Benefit in Advanced Urothelial Cancer
07/27/2020
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
Pembrolizumab was active in...
07/27/2020
Oncology
News
FDA Approves Avelumab for Advanced or Metastatic Urothelial Carcinoma
07/01/2020
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing chemotherapy.
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing chemotherapy.
The FDA approved avelumab for...
07/01/2020
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
News
Switch Maintenance Pembrolizumab Improves Response, PFS in Metastatic Urothelial Cancer
05/01/2020
Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.
Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.
Switch maintenance pembrolizumab...
05/01/2020
Oncology
News
Teratoma Not A Prognostic Factor in Metastatic Testicular Germ Cell Tumors
05/01/2020
Findings from a large retrospective study suggest that teratoma is not a prognostic factor in patients with metastatic testicular germ cell tumors.
Findings from a large retrospective study suggest that teratoma is not a prognostic factor in patients with metastatic testicular germ cell tumors.
Findings from a large...
05/01/2020
Oncology
News
FDA Approves Mitomycin for Adults With Upper Tract Urothelial Cancer
04/15/2020
The FDA has approved mitomycin for the treatment of adults with low-grade upper tract urothelial cancer.
The FDA has approved mitomycin for the treatment of adults with low-grade upper tract urothelial cancer.
The FDA has approved mitomycin...
04/15/2020
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement